logo

For the Inventor, By the Inventor

Princeton, MA, United States of America

Timothy F Kowalik

USPTO Granted Patents = 13 

Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Princeton, NJ (US) (2015 - 2019)
  • Princeton, MA (US) (2010 - 2024)

Company Filing History:

goldMedal13 out of 1,556 
 
University of Massachusetts
 patents

Years Active: 2010-2025

Loading Chart...
13 patents (USPTO):Explore Patents
1. 12268901 - Targeting cell tropism receptors to inhibit cytomegalovirus infection (2025-04-08),
2. 12091664 - Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation (2024-09-17),
3. 12084660 - Therapeutic alteration of transplantable tissues throughorexposure to RNA interference molecules (2024-09-10),
4. 11484570 - Targeting cell tropism receptors to inhibit cytomegalovirus infection (2022-11-01),
5. 11220686 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules (2022-01-11),
6. 10260066 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules (2019-04-16),
7. 10227591 - Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212) (2019-03-12),
8. 9562232 - Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212) (2017-02-07),
9. 9150861 - [object Object] (2015-10-06),
10. 8940709 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules (2015-01-27),
11. 8933045 - Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (mi145) and micro-RNA 212 (miR212) (2015-01-13),
12. 8361976 - Therapeutic alteration of transplantable tissues through in situ or ex vivo exposure to RNA interference molecules (2013-01-29),
13. 7776569 - Virally-encoded RNAs as substrates, inhibitors and delivery vehicles for RNAi (2010-08-17),

Title: Innovations and Contributions of Timothy F. Kowalik

Introduction

Timothy F. Kowalik is a prominent inventor based in Princeton, MA (US), known for his significant contributions to the field of medical research and innovation. With a total of 13 patents to his name, he has made remarkable strides in developing methods to combat viral infections and improve transplant outcomes.

Latest Patents

Among his latest patents, one notable invention focuses on targeting cell tropism receptors to inhibit cytomegalovirus infection. This method involves administering inhibitors of Deleted in Malignant Brain Tumors 1 (DMBT1), OR14I1, or adenylyl cyclases to reduce the risk of cytomegalovirus infection in subjects. Another significant patent addresses methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation. This invention provides techniques for treating ischemia in transplant donor tissue by using RNA interference (RNAi) to target genes that mediate ischemic injury, thereby decreasing the risk of tissue rejection and promoting immunological tolerance.

Career Highlights

Timothy F. Kowalik is affiliated with the University of Massachusetts, where he continues to advance his research and innovation efforts. His work has garnered attention for its potential to improve patient outcomes in both viral infections and organ transplantation.

Collaborations

Throughout his career, Kowalik has collaborated with esteemed colleagues, including Marc E. Ukn

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…